| Keywords: |
signal transduction; gene mutation; proto-oncogene proteins; erlotinib; cancer combination chemotherapy; drug targeting; imatinib; drug inhibition; gene amplification; lung non small cell cancer; antineoplastic combined chemotherapy protocols; lung neoplasms; epidermal growth factor receptor; lung cancer; receptor, epidermal growth factor; drug resistance; drug resistance, neoplasm; drug development; abelson kinase; dasatinib; cancer resistance; oncogene; glioblastoma; drug response; carcinogenicity; gefitinib; tumor cell; cancer relapse; short survey; tumor; epidermal growth factor receptor 3; phosphotransferase inhibitor; disease treatment; receptors, platelet-derived growth factor; receptors, growth factor; myeloid leukemia; drug mixture
|
